Patient in this case report is a 70-year-old female. When this patient was presented at the clinic, she was non-verbal and incapacitated. Patient had previously been diagnosed with lung disease/lung cancer. In addition, there was a non-healing bedsore wound on the left cheek/sacrum measuring 38 cm² in circumference and 1.6 cm in depth.

Treatment of the sacral wound was immediately commenced. The existing bandage was removed, the wound area was then rinsed lightly with saline, and a DermaBind TL allograft (6.5 cm x 6.5 cm) was placed directly on the wound. The allograft was covered with cotton gauze and a zinc solution spray. The allograft was left on the wound for 6 days at which time a new allograft was placed over the previously applied grafts. When a new allograft was applied (approximately each week), the circumference of the wound and depth of the wound were measured to assess progression of the wound toward closure. This treatment regimen continued for 4 weeks.

Weekly Measurements

Treatment Expectations & Outcomes

Based on previous uses of DermaBind TL, the expectation was that the wound would progress from the non-healing state to a healing state. A four-week timeline was not expected to result in a full closure of the wound but significant progress was expected to occur.

Results achieved: The wound circumference was reduced by an average of nearly 7 cm² per week over the 4-week treatment period.

A patient, 70F, with a non-healing sacral wound, was treated using DermaBind TL for 4 weeks. During this 4 week period, there was a significant reduction in the circumference and the depth of the sacral wound. Through the four weeks of treatment, the wound circumference was reduced by an average of nearly 7 cm² per week. This patient's treatment was scheduled to be extended to 12 weeks with the expectation that the use of DermaBind TL could bring this wound to a complete closure. Unfortunately, this patient was deceased before the study could be reached 5 weeks.

The purpose of this case study was to assess the feasibility, ease of use and safety associated with the use of this novel full-thickness placental membrane allograft. The sacral wound treated with DermaBind TL experienced at least a 50% reduction in wound area within 3 weeks of initial application. The authors believe that this is the only case reported in the literature of the use of this therapy. Considering that this patient had previously failed conventional wound treatments, the results obtained support the hypothesis that full-thickness placental membrane allografts are effective in promoting wound healing. No adverse events were observed in the study.

DermaBind TL offers an effective and easy-to-use treatment alternative for the management of chronic wounds. Clinical improvement results strongly suggest significant and faster healing, resulting in complete wound closure, in wounds treated with full-thickness placental membrane-containing products. Chronic wounds that do not respond to other standard treatment options show significant healing and wound coverage with placental membranes. Easy storage and extended shelf life promote clinical acceptance in the wound care environment. Lower complication rates compared to other similar products have been reported in numerous clinical studies. Although DermaBind TL has a higher unit (dressing) cost compared to standard wound care, the overall cost is similar or lower considering the faster healing and presumably lower rate of complications and clinical sequelae such as amputations.